PGEN Stock Price, Chart, Stats & News
Precigen Inc (PGEN) does not currently pay a dividend.
PGEN chart
Fundamentals
Gross margin | 42.13% |
Operating margin | -1141.13% |
Pretax margin | -2588.18% |
Net margin | -2588.21% |
Effective tax rate | -0.00% |
ROA | -160.03% |
ROE | -8396.72% |
D/E | 0.24x |
Interest coverage ratio | -28.58x |
PGEN valuation
P/E | – |
P/S | 113.86x |
P/B | 54.93x |
P/CF | -13.08x |
P/FCF | -12.19x |
P/OCF | -13.08x |
PEG | -0.05x |
EV multiple | -4.59x |
About
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination.
Similar securities
Based on sector and market capitalization
